drugset
drugset / Trial / NCT00703703

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

NCT00703703 ↗

Phase 1 Completed 117 enrolled Novartis Procter and Gamble · collab
RandomizedCrossoverDouble-blindTreatment

Summary

This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older

Timeline

Start
2008-05
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Darifenacin Small molecule 15 mg —
Comparator Tolterodine Unknown 4 mg —

Indications

No indication recorded.